Latest Industry Insights

Recent legislation changes by Health Canada have seen psychedelics become easier to prescribe for a range of mental health conditions. We spoke to Alexander Somjen, CEO of Origin Therapeutics, to find out what the impact of these changes will be for physicians, patients and providers.

Technology Networks spoke to Dr. Mark Kotter, CEO and founder of bit.bio to learn about opti-ox™ and the development, benefits and applications of ioSkeletal Myocytes.

Technology Networks had the pleasure of speaking with Saul Kato, the CEO of Herophilus, to learn more about how the company plans to reinvent neuro drug discovery, by combining human brain models, scaled biology and machine learning to decode brain disease.

Brain-computer interface (BCI) developer Blackrock Neurotech has announced that its MoveAgain BCI has received Breakthrough Device designation from the US Food and Drug Administration (FDA). To find out more, we spoke with Blackrock’s chairman and president, Florian Solzbacher.

We spoke to co-founder and executive chairman, Ronan Levy, to find out more about Field Trip’s approach to psychedelic therapy and why 2021 has been such a significant year in psychedelics.

The revival of psychedelic medicine is well underway. We spoke with Small Pharma CEO Peter Rands to discuss the unique features of the psychedelic DMT and updates from the company’s latest trials.

Poor mental health is a growing burden on global healthcare systems. In this opinion piece, Compass Pathways chief medical officer Professor Guy Goodwin reviews currently available treatments options and the results from his company's new clinical trial into the efficacy of the psychedelic psilocybin in treating mental health conditions.

To learn more about a universal vaccine technology and how the platform could be applied to Alzheimer's disease and other neurological indications, Technology Networks spoke with Roman Kniazev, chief executive officer at Nuravax.

While most psychedelic drugs remain illegal in the United States, ketamine has been legal for use by registered practitioners since the 1960s. With the recent recognition of the compound’s use as an antidepressant, more and more clinics are rolling out ketamine-assisted psychotherapy programs.

Psilocybin – the primary active ingredient in magic mushrooms – is to be studied in a new clinical trial that will test whether the psychedelic compound can help people quit smoking.